ActoMeg Tablet 15 mg + 850 mg is a potent combination antidiabetic medication formulated for the effective management of type 2 diabetes mellitus. Each tablet contains Pioglitazone 15 mg and Metformin Hydrochloride 850 mg, two well-established oral hypoglycemic agents that work through complementary mechanisms to improve glycemic control in adults. ActoMeg is designed to be part of a comprehensive diabetes care plan involving diet modification, exercise, and regular blood glucose monitoring.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Key Active Ingredients

• Pioglitazone 15 mg
  Pioglitazone belongs to the thiazolidinedione class of drugs. It enhances the body’s sensitivity to insulin, helping peripheral tissues such as muscle and adipose tissue use insulin more effectively. It also reduces hepatic glucose production. This action improves blood glucose control and assists in achieving target glycemic levels with lower circulating glucose.

• Metformin Hydrochloride 850 mg
  Metformin is a biguanide antihyperglycemic agent. It primarily reduces excessive hepatic glucose output and enhances insulin sensitivity in peripheral tissues. Metformin also improves glucose uptake and utilization without causing significant weight gain. It has a well-established safety profile and is considered a first-line therapy in type 2 diabetes.

Indications

ActoMeg Tablet 15 mg + 850 mg is indicated for:

• Management of Type 2 Diabetes Mellitus
  As an adjunct to diet and exercise in patients whose blood glucose levels are not adequately controlled with monotherapy (metformin or pioglitazone alone).

• Combination Therapy
  Suitable for patients already on metformin therapy who require additional glycemic control or those transitioning from another combination regimen.

Mechanism of Action

ActoMeg leverages dual-mechanism glycemic control:

• Enhanced Insulin Sensitivity: Pioglitazone activates PPAR-gamma receptors, improving cellular response to insulin and reducing insulin resistance.

• Lowered Glucose Production: Metformin lowers hepatic gluconeogenesis (glucose production) and increases peripheral glucose uptake, thereby reducing fasting and postprandial blood glucose.

By addressing both insulin resistance and excessive glucose production, ActoMeg helps maintain more stable and predictable blood glucose levels.

Benefits

• Improved Glycemic Control: Effective reduction in both fasting plasma glucose and HbA1c levels.

• Complementary Actions: Dual mechanism supports better metabolic control than either component alone.

• Weight Neutral or Benefits: Metformin is weight neutral; combined therapy can help prevent weight gain often seen with other antidiabetics.

• Cardiovascular Profile: Pioglitazone has demonstrated favorable effects on certain cardiovascular risk markers in specific patient groups, under medical supervision.

• once-to-twice daily dosing: Enhances compliance and convenience.

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Dosage & Administration

ActoMeg should be taken as prescribed by a healthcare provider, typically once or twice daily with meals to minimize gastrointestinal side effects. The dosage may be titrated based on individual glycemic response, tolerability, and clinical parameters. Regular monitoring of blood glucose and HbA1c is recommended to assess effectiveness and adjust therapy.

Safety & Precautions

• Not for Type 1 Diabetes: ActoMeg is not effective for patients with type 1 diabetes or diabetic ketoacidosis.

• Renal & Hepatic Monitoring: Periodic assessment of kidney and liver function is recommended, particularly in patients with existing organ impairment.

• Heart Failure Caution: Pioglitazone may cause fluid retention; use cautiously in patients with or at risk of heart failure.

• Gastrointestinal Effects: Metformin may cause nausea, diarrhea, or abdominal discomfort, typically transient and dose-related.

Always inform your healthcare provider of all concomitant medications and medical conditions before starting ActoMeg.